Deutsche Bank AG set a €55.00 ($63.95) target price on Stratec Biomedical AG (ETR:SBS) in a research note released on Thursday. The brokerage currently has a neutral rating on the stock.

A number of other equities research analysts have also issued reports on the company. Kepler Capital Markets set a €66.00 ($76.74) price target on Stratec Biomedical AG and gave the company a buy rating in a research report on Wednesday, July 26th. Warburg Research set a €62.00 ($72.09) price objective on Stratec Biomedical AG and gave the stock a buy rating in a research report on Tuesday, July 25th. Berenberg Bank set a €59.00 ($68.60) price objective on Stratec Biomedical AG and gave the stock a neutral rating in a research report on Tuesday, July 25th. Finally, Oddo Securities set a €58.00 ($67.44) price objective on Stratec Biomedical AG and gave the stock a neutral rating in a research report on Monday, July 24th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average price target of €60.00 ($69.77).

Shares of Stratec Biomedical AG (SBS) opened at 51.924 on Thursday. The company’s 50 day moving average price is €57.73 and its 200-day moving average price is €54.04. The company has a market capitalization of €617.27 million and a price-to-earnings ratio of 32.072. Stratec Biomedical AG has a 52 week low of €41.45 and a 52 week high of €63.18.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/stratec-biomedical-ag-etrsbs-pt-set-at-55-00-by-deutsche-bank-ag/1463039.html.

About Stratec Biomedical AG

Stratec Biomedical AG (Stratec) is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of clinical diagnostics and biotechnology. It is primarily active in the in vitro diagnostics industry and focuses on the segment in-vitro diagnostics, clinical diagnostics as well as molecular diagnostics.

Analyst Recommendations for Stratec Biomedical AG (ETR:SBS)

Receive News & Ratings for Stratec Biomedical AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stratec Biomedical AG and related companies with Analyst Ratings Network's FREE daily email newsletter.